Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 21;10:1299. doi: 10.3389/fonc.2020.01299

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Britschgi, Addeo, Rechsteiner, Delaloye, Früh, Metro, Banini, Gautschi, Rothschild, Wild, Banna and Curioni-Fontecedro.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

OS curves (median follow-up of 39.5 months, 95% CI: 32.1–77.7). (A) OS of all patients, median 48.0 months (95% CI: 12.9–83.0). (B) OS according to the first-line of treatment, first-line TKI median 35.8 months (95% CI NA) vs. first-line ChT 48.0 months (95% CI: 11.8–84.1) (p = 0.955). (C) OS according to the number of lines of TKIs, >one line of TKIs median 85.7 months (95% CI: 63.9–107.5) vs. one line of TKI 34.8 months (95% CI: 21.6–48.0; p = 0.016). (D) OS according to the use of alectinib or lorlatinib in any line. Alectinib/lorlatinib median 85.7 months (95% CI: 64.0–107.5) vs. crizotinib ± ceritinib 37.3 months (95% CI: 16.1–58.6; p = 0.022). ChT, chemotherapy; CI, confidence interval; NA, not assessable; No., number; OS, overall survival; TKI, tyrosine kinase inhibitor.